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Abstract
Background: An alarming portion of patients develop persistent or chronic pain following surgical procedures, but the
mechanisms underlying the transition from acute to chronic pain states are not fully understood. In general, endocannabinoids
(ECBs) inhibit nociceptive processing by stimulating cannabinoid receptors type 1 (CB1)a n dt y p e2( C B 2). We have previously
shown that intrathecal administration of a CB2 receptor agonist reverses both surgical incision-induced behavioral
hypersensitivity and associated over-expression of spinal glial markers. We therefore hypothesized that endocannabinoid
signalingpromotestheresolutionofacutepostoperativepainbymodulatingpro-inflammatorysignalinginspinalcordglialcells.
Methodology/Principal Findings: To test this hypothesis, rats receiving paw incision surgery were used as a model of acute
postoperative pain that spontaneously resolves. We first characterized the concentration of ECBs and localization of CB1 and
CB2 receptors in the spinal cord following paw incision. We then administered concomitant CB1 and CB2 receptor
antagonists/inverse agonists (AM281 and AM630, 1 mg.kg
21 each, i.p.) during the acute phase of paw incision-induced
mechanical allodynia and evaluated the expression of glial cell markers and phosphorylated p38 (a MAPK associated with
inflammation) in the lumbar dorsal horn. Dual blockade of CB1 and CB2 receptor signaling prevented the resolution of
postoperative allodynia and resulted in persistent over-expression of spinal Glial Fibrillary Acidic Protein (GFAP, an astrocytic
marker) and phospho-p38 in astrocytes. We provide evidence for the functional significance of these astrocytic changes by
demonstrating that intrathecal administration of propentofylline (50 mg, i.t.) attenuated both persistent behavioral
hypersensitivity and over-expression of GFAP and phospho-p38 in antagonist-treated animals.
Conclusions/Significance: Our results demonstrate that endocannabinoid signaling via CB1 and CB2 receptors is necessary
for the resolution of paw incision-induced behavioral hypersensitivity and for the limitation of pro-inflammatory signaling in
astrocytes following surgical insult. Our findings suggest that therapeutic strategies designed to enhance endocannabinoid
signaling may prevent patients from developing persistent or chronic pain states following surgery.
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Introduction
Following surgical procedures such as hernia repair, breast
surgery, thoracotomy, cesarean section or coronary artery bypass
surgery, patients develop acute postoperative pain that is
characterized by mechanical hypersensitivity (pain due to
ambulation, cough or manipulation of the surgical incision area).
While this acute postoperative pain typically resolves, 10-50% of
patients experience persistent postsurgical pain despite analgesic
treatment, and 2-10% of patients develop severe chronic pain
(rates depend on the procedure) [1]. The clinical treatment of
persistent or chronic pain is frequently complicated by the limited
efficacy and undesirable side effects of currently available analgesic
drugs. The development of safer, more effective analgesics for the
management of persistent postoperative pain requires a better
understanding of the mechanisms by which tissue injury-induced
acute pain can develop into chronic pain.
In general, stimulation of the G protein-coupled cannabinoid
receptors types 1 and 2 (CB1 and CB2) results in inhibition of
nociceptive signaling pathways (reviewed in [2]). Plant-derived and
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antinociceptive effects [3,4,5], but endogenous cannabinoid
compounds, or endocannabinoids (ECBs), have also gained
attention for their ability to modulate pain pathways. The two
main ECBs, anandamide (AEA) and 2-arachidonoylglycerol (2-
AG), inhibit nociception following exogenous administration [6,7]
and have been shown to mediate stress-induced [8] and fear-
conditioned [9] analgesia. Inhibitors of endocannabinoid reuptake
[10,11] or degradation [12,13,14] also produce antinociceptive
effects. Based on these findings, it has been suggested that the
endocannabinoid system mediates an adaptive response aimed at
reducing pain and inflammation in response to injury or stress
[15]. We therefore hypothesized endocannabinoid signaling is
necessary to prevent the perpetuation of acute postoperative pain
following surgical insult.
To test this hypothesis, we used a model of postoperative pain in
rats that consists of a small incision made on the plantar surface of
one hind paw [16]. Following paw incision, animals exhibit
significant mechanical allodynia and an associated increase in the
expression of glial markers, both of which spontaneously resolve
over the course of approximately one week [16,17]. Based on our
previous findings that intrathecal administration of a CB2 receptor
agonist reverses both behavioral hypersensitivity and associated
over-expression of glial markers resulting from paw incision [3],
we further hypothesized that endocannabinoid signaling contrib-
utes to the resolution of postoperative pain by limiting pro-
inflammatory responses in spinal cord glial cells.
In the current study, we first characterized tissue concentrations
of ECBs and the overall expression and cellular localization of CB1
and CB2 receptors in the spinal cord following paw incision. To
test our main hypothesis, we then introduced a dual blockade of
CB1 and CB2 receptors during the acute phase of paw incision-
induced mechanical allodynia. Using this approach, we demon-
strated that ECB signaling plays a functional role in the resolution
of postoperative pain and in regulating the expression of glial cell
markers and phosphorylated p38 (a MAPK associated with
inflammation [18]).
Results
Mechanical Allodynia and Expression of Glial Markers
following Paw Incision
Animals were tested for mechanical allodynia at days 1, 3 and 9
following surgery to establish a behavioral basis for the
characterization of ECB levels and spinal expression of CB1 and
CB2 receptor in response to paw incision. Withdrawal thresholds
of the injured paw (ipsilateral to paw incision) were significantly
reduced on days 1 and 3 after surgery compared to baseline values.
By day 9 after paw incision, however, this mechanical hypersen-
sitivity had resolved (Figure 1A). Similarly, no significant
differences were found between baseline withdrawal thresholds
and those observed on day 15 after surgery (19.0460.4 g vs.
17.6460.1 g, p.0.05). On all postoperative days tested,
mechanical withdrawal thresholds of the uninjured paw (contra-
lateral to paw incision) did not significantly differ from baseline
values (data not shown). In agreement with our previous
quantitative findings [17], both Ionized Calcium–Binding Adapter
Molecule 1 (Iba-1, microglial marker) and Glial Fibrillary Acidic
Protein (GFAP, astrocytic marker) demonstrated increased
immunostaining in the ipsilateral dorsal horn of the L5 spinal
cord on postoperative days 1 and 3 but returned to basal levels by
day 9 (Figure 1B). The number of ED2/CD163-positive cells in
the ipsilateral dorsal horn did not significantly change following
paw incision (data not shown).
Endocannabinoid Concentrations in the Spinal Cord and
PAG following Paw Incision
Endocannabinoids, other fatty acid ethanolamides (FAEs) and
their N-acylphosphatidylethanolamine species (NAPEs) precursors
were detected in the lumbar spinal cord of naı ¨ve animals and animals
at days 1, 3, 9 and 15 after paw incision surgery. In animals receiving
paw incision surgery, the concentrations of AEA in both the
ipsilateral and contralateral lumbar spinal cord were significantly
lower on postoperative days 1 and 3 compared to basal concentra-
tions in naı ¨ve animals. On postoperative days 9 and 15, however,
levels of spinal AEA were no longer significantly different from those
observed in naı ¨ve animals (Figure 2). Spinal concentrations of N-
arachidonoylphosphatidylethanolamine (NAPE), a precursor of
AEA, demonstrated no significant differences from basal concentra-
tions at any postoperative time point tested, indicating that the
observed changes in AEA concentration may have resulted from
altered rates of degradation rather than synthesis (Table S1).
In contrast, the concentration of 2-AG in the ipsilateral spinal
cord did not significantly differ from basal levels on day 1 after
paw incision, but was significantly higher on days 3 and 9 before
returning to basal levels on day 15 (Figure 2). In the contralateral
spinal cord, tissue concentrations of 2-AG were significantly
increased on days 1 and 9 but did not significantly differ from
basal levels on days 3 and 15 after paw incision (Figure 2). In the
lumbar spinal cords of naı ¨ve animals, concentrations of 2-AG were
approximately 100-fold higher than those of AEA, in agreement
with previous analyses of central nervous system tissues [19,20].
In both the contralateral and ipsilateral spinal cord, tissue
concentrations of the lipid amide palmitoylethanolamide (PEA), its
analog, (N-oleoylethanolamine) OEAand their respective precursors,
N-palmitoylphosphatidylethanolamine (NPPE) and N-oleoylpho-
sphatidylethanolamine (NOPE), did not significantly differ from
basal values at any postoperative time point tested (Figure S1 and
Table S1). The concentration of PEA in the periaqueductal gray
(PAG) was significantly lower in animals at days 1, 9 and 15 (but not
on day 3) after surgery than in naı ¨ve animals (Figure S2). However,
compared to basal concentrations, we did not observe significant
changes in NAPE, NPPE, NOPE, OEA,AEA or 2-AG in the PAG at
any postsurgical time point studied (Figure S2 and Table S1).
Spinal Cord CB1 and CB2 Receptor Expression and
Cellular Localization
In order to characterize the targets of the endocannabinoid
system following paw incision, we evaluated the relative staining of
spinal CB1 and CB2 receptors over time and examined their
cellular localization. CB1 receptor staining in the L5 dorsal horn
was significantly reduced on postoperative days 1 and 9 and spinal
CB2 receptor staining was significantly increased on day 1
compared to staining in naı ¨ve animals (Figures S3 and S4).
In both naı ¨ve animals and animals receiving paw incision, spinal
CB1 receptors were primarily expressed on NeuN-positive neurons
(Figure 3). On occasion CB1 receptor staining also appeared to co-
localize with GFAP, an astrocyte marker (Figure 3). These findings
were confirmed using a 3-dimensional animation of Z-stack layered
confocal images (Videos S1 and S2). Microglia (Iba-1 positive cells)
and perivascular microglial cells (ED2/CD163 positive cells) did not
co-localize with CB1 receptor staining in naı ¨ve animals or at any
observed time following paw incision (Figure 3).
Microglia (Iba-1 positive cells) and perivascular microglia
(ED2/CD163 positive cells) did, however, demonstrate localized
areas of strong CB2 receptor staining (Figure 4). CB2 receptor
staining was occasionally observed on NeuN-positive neuronal
somata but was punctate and relatively diffuse in character
Endocannabinoids in Acute Pain
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not demonstrate CB2 receptor expression (Figure 4).
Behavioral Effects of CB1 and CB2 Receptor Blockade
following Paw Incision
To our knowledge, CB1 and CB2 receptors have not previously
been implicated in the resolution of postoperative pain. We aimed
to produce a complete blockade of ECB signaling via these
receptors by systemically administering mixed CB1 and CB2
antagonists/inverse agonists (AM281 + AM630; 1 mg.kg
21 each,
i.p.) to rats on the day of paw incision surgery and twice daily for
the following nine days. Control animals were treated with vehicle
according to the same paradigm. On postoperative day 1, both
groups similarly demonstrated significantly lower withdrawal
thresholds in the injured paw but not the uninjured paw as
compared to baseline values (Figure 5). By day 8 (and subsequent
days), however, the ipsilateral withdrawal thresholds of vehicle-
treated animals were significantly higher than their day 1 values
(p,0.05), indicating the resolution of paw incision-induced
mechanical allodynia (Figure 5). In contrast, the ipsilateral
withdrawal thresholds in the AM281 + AM630 group did not
differ significantly from their day 1 levels at any time point tested
(p.0.05) and were significantly lower than the vehicle group at
day 8 and subsequent days (Figure 5). The significant difference
between groups persisted through postoperative days 12-15, after
administration of AM281 + AM630 had been discontinued (day 9
was the last day of treatment).
In vehicle-treated animals, the withdrawal thresholds of the
uninjured paw (contralateral to paw incision) did not significantly
differ from baseline values on any days tested (p.0.05). In
contrast, animals treated chronically with AM281 + AM630
demonstrated a significant decrease in contralateral withdrawal
thresholds on days 7, 8 and 9 compared to baseline values
(p,0.05) and on day 9 compared to vehicle-treated animals
(Figure 5). However, on days 12-15, after the AM281 + AM630
treatment had been discontinued, contralateral withdrawal
thresholds were no longer significantly different from baseline
values or from vehicle controls (Figure 5). To monitor the acute
effects of AM281 + AM630 treatment, animals in preliminary
trials were tested before and 30 minutes, 1 hour and 2 hours after
drug or vehicle injections (n=6 per group). On every day tested
(postoperative days 1-9), AM281 + AM630 injection produced no
significant changes in mechanical withdrawal thresholds at these
acute time points (data not shown).
Figure 1. Paw incision-induced mechanical allodynia and increased glial marker expression spontaneously resolve. (A) 50% paw withdrawal
thresholds were evaluated in naı ¨ve animals and ipsilateral to paw incision in animals at days 1, 3 and 9 after surgery (n=8 per group). *p,0.05 vs. baseline
values by one-way ANOVA repeated measures followed by Dunnett’s post test. #p,0.05 vs. postoperative day 1 values by one-way ANOVA repeated
measures followed by Dunnett’s post test. (B) L5 spinal cord sections were stained for Iba-1 (green) and GFAP (red). Representative confocal images show
detail of the superficial laminae of the L5 dorsal horn in naı ¨ve animals and ipsilateral to paw incision in rats at days 1, 3 and 9 after surgery. BL: Baseline.
doi:10.1371/journal.pone.0010891.g001
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Iba-1 and ED2/CD163 following Paw Incision
On day 9 following surgery, both the superficial (I-II) and deeper
laminae (III-V) of the ipsilateral L5 dorsal horn demonstrated
significantly stronger GFAP staining in animals treated with AM281
+ AM630 than in vehicle-treated animals (Figures 6A and 6C). On
day 9, GFAP staining in the contralateral dorsal horn (laminae I-II)
was also significantly stronger in animals treated with AM281 +
AM630 than in vehicle-treated animals (202.5664.1 vs. 41.663.7
pixels per 1000, AM281 + AM630 and vehicle groups respectively,
p,0.05). At the same time point we observed no significant differences
between groups in Iba-1 staining of the ipsilateral (Figures 6A and 6C)
or contralateral (21.463.7 vs. 11.561.0 pixels per 1000, AM281 +
AM630 and vehicle groups respectively, p.0.05) L5 dorsal horn.
On postoperative day 15 (six days after AM281 + AM630
treatment was discontinued), GFAP staining remained significantly
stronger in the ipsilateral L5 dorsal horn (laminae I-II) of mixed
antagonist-treated animals than in vehicle-treated animals (Figure 6B
and 6C) but no significant differences between groups were observed
in the contralateral dorsal horn (368.1662.1 vs. 239.167.7 pixels per
1000, AM281 + AM630 and vehicle group respectively, p.0.05). At
this time point, Iba-1 staining did not significantly differ between
groups in either the ipsilateral (Figure 6B and 6C) or contralateral
(15.862.0 vs. 12.161.1 pixels per 1000, AM281 + AM630 and
vehicle groups respectively, p.0.05) L5 dorsal horn. At day 15, the
number of spinal ED2/CD163-positive cells did not significantly
differ between groups (data not shown).
Effect of Propentofylline in Animals Treated with Dual
CB1 and CB2 Receptor Blockade
We then sought to evaluate whether the observed astrocytic
response played a functional role in the persistent hypersensitivity
observed in animals treated chronically with AM281 + AM630.
We confirmed that concomitant AM281 + AM630 administered
from the day of surgery to postoperative day 9 delayed the
resolution of paw incision-induced allodynia through postoperative
day 15. We also confirmed that after 9 days this treatment induced
significant allodynia in the uninjured paw. On postoperative days
14 and 15, we then treated a subset of animals from the AM281 +
AM630 group intrathecally (i.t.) with propentofylline (50 mg;
hereafter referenced as the ‘AM281 + AM630/PPF group’) or
vehicle (saline; hereafter referenced as the ‘AM281 + AM630/
Saline group’). Propentofylline is an atypical methylxanthine that
has been shown to attenuate both mechanical allodynia and
associated increases in glial marker and algesic factor expression in
a model of neuropathic pain [21,22,23]. Three hours after
injection on both days that propentofylline or vehicle was
administered (days 14 and 15), animals in the AM281 +
AM630/PPF group displayed ipsilateral withdrawal thresholds
that were significantly than AM281 + AM630/Saline controls
(Figure 7). Three hours after treatment on day 15, the ipsilateral
withdrawal thresholds of AM281 + AM630/PPF animals were not
significantly different from pre-surgery baseline values (Figure 7).
We then used immunostaining to evaluate the effects of
propentofylline treatment on relative expression of GFAP and the
phosphorylated form of p38, a mitogen activated protein kinase
(MAPK) associated with a pro-inflammatory cellular phenotype [18].
In addition to producing a persistent increase in spinal GFAP staining
(Figure8),treatmentwithAM281+AM630 alsoresulted inincreased
phospho-p38 staining (Figure 8). Using confocal microscopy, we
observed that phospho-p38 was expressed mainly in astrocytes
(GFAP-positive cells) but was also expressed in perivascular microglia
(ED2/CD163-positive cells, Figure 9). Spinal cord sections from the
AM281 + AM630/PPF group demonstrated significantly lower
GFAP and pospho-p38 staining compared to sections from AM281 +
AM630/Saline animals, indicating that propentofylline treatment
had reversed the persistent increase in spinal GFAP expression and
p38 phosphorylation induced by the dual CB1/CB2 receptor
blockade (Figure 8).
Figure 2. Spinal endocannabinoid levels are dynamically regulated following paw incision. Spinal cord concentrations of AEA and 2-AG
were determined in the lumbar spinal cord of naı ¨ve rats (N, n=3) and in the ipsilateral and contralateral lumbar spinal cord of rats at days 1 (D1), 3
(D3), 9 (D9) and 15 (D15) after paw incision surgery (n=6 for each group). *p,0.05 vs. naı ¨ve group by one-way ANOVA followed by Dunnett’s post
test. 2-AG: 2-Arachidonoylglycerol, AEA: Anandamide.
doi:10.1371/journal.pone.0010891.g002
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Despite widespread recognition of the role of endocannabinoids
in regulating pain pathways, the role of the ECB system in the
resolution of acute pain following peripheral tissue damage has
not, to our knowledge, been previously described. In the current
study we used a rat model of postoperative pain to demonstrate
that dual blockade of CB1 and CB2 receptor signaling prevented
the resolution of postoperative allodynia and led to a persistent
increase of spinal GFAP expression and astrocytic p38 phosphor-
Figure 3. Spinal CB1 receptors are mainly expressed in neurons. Confocal analysis was used to determine spinal CB1 receptor cellular
localization in the superficial laminae of the L5 dorsal horn in naı ¨ve rats or ipsilateral to surgery in rats at days 1, 3 and 9 after paw incision.
Representative images are shown. CB1 receptor staining appears in red. NeuN (marker for neurons), Iba-1 (marker for microglia) and ED2/CD163 (ED2,
marker for perivascular microglia) appear in green. GFAP (marker for astrocytes) appears in grey. In the images of CB1 receptors and Iba-1, CB1
receptor staining originally appeared green, and Iba-1 appeared in red. These colors were digitally switched in order to consistently represent CB1
receptor staining in red in all images. In the images of CB1 receptors and GFAP, GFAP staining originally appeared in green. The color of GFAP staining
was digitally changed to grey in order to allow better visualization of occasional staining of CB1 receptors on GFAP-positive cells. The colocalization of
CB1 receptors and NeuN staining appears in yellow.
doi:10.1371/journal.pone.0010891.g003
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these astrocytic changes by demonstrating that intrathecal
administration of propentofylline attenuated both persistent
hypersensitivity and over-expression of GFAP and phospho-p38
in animals treated with AM281 + AM630.
Anandamide and 2-AG act mainly on CB1 and CB2 receptors
to modulate both normal physiology and disease pathogenesis in a
host of biological systems, including nociceptive processing
(reviewed in [15]). We found that AEA was reduced in the spinal
cord at the time of maximum mechanical hypersensitivity
Figure 4. Spinal CB2 receptors are mainly expressed in microglial cells. Confocal analysis was used to determine CB2 receptor cellular
localization in the superficial laminae of the L5 dorsal horn in naı ¨ve rats or ipsilateral to surgery in rats at days 1, 3 and 9 after paw incision.
Representative images are shown. CB2 receptor staining appears in red. NeuN (marker for neurons), Iba-1 (marker for microglia) and ED2/CD163
(ED2, marker for perivascular microglia) appear in green. GFAP (marker for astrocytes) appears in grey. In the images of CB2 receptors and GFAP,
GFAP staining originally appeared in green. The color of GFAP staining was digitally changed to grey in order to allow a better visualization of this
specific marker and any potential staining of CB2 receptors. The colocalization of CB2 receptors with the other cellular markers is visualized in
yellow.
doi:10.1371/journal.pone.0010891.g004
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to basal levels by the time paw incision-induced allodynia had
spontaneously resolved (postoperative days 9 and 15). In
agreement with these results, previous studies using rodent models
have shown that decreased ECB levels may mediate nociceptive
sensitization arising from other disease states, such as bone cancer
[24] or migraine [25]. We also observed that spinal cord levels of
2-AG were not reduced but rather increased during the phase of
postoperative pain resolution (days 3 and 9 after surgery). Taken
together, these results suggest that low levels of AEA in the spinal
cord may contribute to paw incision-induced allodynia, and that
the normalization of spinal AEA concentrations paired with
elevated 2-AG may contribute to the spontaneous resolution of
behavioral hypersensitivity. This conclusion is supported by our
subsequent finding that chronic administration of mixed CB1 and
CB2 receptor antagonists/inverse agonists resulted in persistent
mechanical allodynia. While our approach cannot rule out the
involvement of other systems, these findings strongly suggest that
cannabinoid receptor signaling is required for the spontaneous
resolution of postoperative pain. In agreement with our results,
CB1 [26] and CB2 [27] receptor knock-out mice display increased
behavioral sensitivity in various models of pain. By day 9, twice-
daily treatment with mixed cannabinoid receptor antagonists
resulted in significant hypersensitivity of the uninjured paw and
associated increases in spinal GFAP staining of the superficial
dorsal horn contralateral to injury, as compared to vehicle
controls. These findings suggest that cannabinoid receptors may
also play a role in the maintenance of basal nociceptive signaling.
However, in the absence of injury, neither of these contralateral
effects was apparent once treatment was discontinued.
The enhancement of glial marker expression and glial p38
phosphorylation is evident in rodent models of acute postoperative
and neuropathic pain. In the former case, the incision-induced
increases in glial marker expression and p38 phosphorylation
spontaneously return to basal levels in association with the
resolution of acute allodynia [3,17,28,29]. Conversely, the
inappropriate persistence of enhanced glial marker expression
and p38 phosphorylation is associated with the generation and
maintenance of chronic pain states [30,31]. In the current study,
the persistent postoperative allodynia induced by the dual CB1/
CB2 receptor blockade was coupled with persistent over-
expression of GFAP and astrocytic phospho-p38, suggesting that
1) lasting astrocytic changes may also contribute to persistent
postoperative pain states and 2) under normal conditions,
endocannabinoid signaling may drive postoperative pain resolu-
tion by directly or indirectly limiting pro-inflammatory signaling in
astrocytes.
In a model of nerve-injury-induced chronic pain, propentofyl-
line has been shown to inhibit hyperalgesia and associated p38
phosphorylation in glial cells [32,33]. Additionally, propentofylline
attenuates GFAP over-expression and increases expression of
glutamate transporter-1 in astrocytes, which may prevent neuronal
sensitization resulting from excess synaptic glutamate [23,34]. In
the current study, propentofylline attenuated both persistent
hypersensitivity and over-expression of GFAP and phospho-p38
in antagonist-treated animals. These results suggest that the
persistence of enhanced astrocytic GFAP and phospho-p38
expression is functionally linked to the behavioral effects of the
dual cannabinoid receptor blockade. In the spinal nerve ligation
model of neuropathic pain, it has been previously shown that the
duration of behavioral hypersensitivity is reduced in GFAP
knockout mice and that intrathecal administration of a GFAP
antisense oligonucleotide reverses hypersensitivity [35]. Although
these findings implicate a functional role of GFAP in neuropathic
pain, it is also possible that these effects are due to mechanisms
upstream (such as nitric oxide, glutamate or substance P signaling
[36]) or downstream (such as myelination, blood–brain barrier
integrity or astrocyte motility [37]) from GFAP expression.
The phosphorylation of glial p38 plays a well-described role in
the production of pro-inflammatory factors (including cytokines,
chemokines, prostaglandins and nitric oxide) that may sensitize
spinal neurons and contribute to the aberrant nociceptive activity
characteristic of chronic pain conditions (reviewed in [18]). In
support of this role, the dephosphorylation of p38 has been shown
to reverse acute postoperative allodynia [30]. Although p38
phosphorylation has thus far been described mainly in microglia
[29,30,33,38,39], p38 has also been shown to participate in the
astrocytic response to a dual CB1/CB2 receptor agonist in vitro
[40]. Together, this in vitro study and our current findings suggest a
functional relationship between astrocytic cannabinoid receptor
signaling and inhibition of p38 phosphorylation. We also observed
the expression of both phospho-p38 and CB2 receptors in
perivascular cells, suggesting that ECBs may also directly regulate
p38 signaling in these cells. Since the number of ED2-positive
perivascular cells was not changed by the dual cannabinoid
receptor blockade, our findings support the idea that an accurate
Figure 5. Dual blockade of CB1 and CB2 receptors prevents the normal resolution of paw incision-induced hypersensitivity.
Withdrawal thresholds ipsilateral (A) and contralateral (B) to paw incision were determined before (BL: Baseline) and following surgery. Mixed
antagonists of CB1 receptors (AM281; 1 mg.kg
21) and CB2 receptors (AM630; 1 mg.kg
21) or vehicle were administered twice daily (i.p.) through day 9
(doted vertical lines). *p,0.05 vs. vehicle group by two-way ANOVA repeated measures followed by Bonferroni post test. n=8 per group.
doi:10.1371/journal.pone.0010891.g005
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PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10891Figure 6. Dual blockade of CB1 and CB2 receptors results in persistent over-expression of GFAP. Representative images show GFAP
(astrocytic marker) and Iba-1 (microglial marker) staining in the L5 dorsal horn ipsilateral and contralateral to paw incision in vehicle- and AM281 +
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obtained by exclusively studying glial marker expression. These
findings also demonstrate the need for further investigation of the
individual contributions of CB1 and CB2 receptor signaling to the
resolution of postoperative pain. The significant effects of
intrathecal propentofylline administration on mechanical allody-
nia and GFAP and phopho-p38 expression support the established
hypothesis that spinal cord mechanisms are integral for the
maintenance of persistent and chronic pain. However, based on
reports of the importance of peripheral cannabinoid receptors in
the induction of analgesia [26,41], the respective roles of
peripheral and central cannabinoid receptors also deserve further
attention in the context of postoperative pain resolution.
Previous studies have demonstrated direct effects of cannabi-
noid compounds on astrocytic function [40,42,43]. In particular,
evidence of ECB-dependent astrocytic-neuronal cross-talk [42]
suggests a mechanism by which the cannabinoid receptor
blockade may result in persistent pro-inflammatory signaling in
astrocytes and contribute to the perpetuation of nociceptive
signaling. Functional interactions between microglia and astro-
cytes may also play a role in mediating the astrocytic response to
changes in ECB signaling. Even though astrocytes do not express
CB2 receptors, genetic deletion of CB2 receptors results in
enhanced GFAP expression in rodent models of neuropathic pain
[27] and Huntington’s disease [44]. Additionally, we have
previously shown that central administration of a CB2 receptor
agonist reduced paw incision-induced GFAP expression [3].
Taken together, these findings suggest that direct effects on
astrocytes, altered neuronal-astrocytic cross-talk and/or altered
microglial-astrocytic interactions may drive the persistent astro-
cytic response that resulted from the dual cannabinoid receptor
blockade.
In conclusion, we have identified CB1 and CB2 receptor-
mediated endocannabinoid signaling as a novel mechanism
underlying the spontaneous resolution of acute postoperative
pain. Our data further suggest that ECB signaling may contribute
to the resolution of postoperative pain by limiting p38 phosphor-
ylation and thereby inhibiting pro-inflammatory signaling in spinal
astrocytes. These results provide a rationale for further investiga-
tion of the role of endocannabinoid signaling in the pathogenesis
of other conditions that may be driven by aberrant glial responses,
such as neurodegenerative diseases [44]. Our findings also suggest
that the dysregulation of ECB signaling may contribute to the
transition from acute to chronic pain states experienced by a
significant portion of surgery patients. Based on these conclusions,
we suggest that therapeutic strategies designed to enhance ECB
signaling may reduce the incidence of persistent postoperative
pain. Further studies are also warranted to evaluate whether these
strategies might prove effective in preventing nerve injury from
developing into chronic neuropathic pain or in treating established
chronic pain with better efficacy and fewer side-effects than
currently available analgesics.
Materials and Methods
Animals and Surgeries
Efforts were made to limit animal distress and to use the
minimum number of animals necessary to achieve statistical
significance. All protocols were previously approved by the
Institutional Animal Care and Use Committee at Dartmouth
College and in accordance with the Guidelines for Animal
Experimentation of the International Association for the Study
of Pain (IASP). Paw incision was used as model of postoperative
pain in rats. The hypersensitivity induced in this model has been
shown to largely resolve by a week after surgery [16,17]. In this
model, male Sprague-Dawley rats (Harlan, Indianapolis, IN)
weighing approximately 250 g at the start of surgery underwent
paw incision surgery as previously described [16]. Briefly, animals
were anesthetized with 4% isoflurane in oxygen by inhalation
followed by maintenance with 2% isoflurane in oxygen. Following
sterilization with 10% providone-iodine solution, a 1 cm midline
incision was made on the plantar face of the left hind paw from the
heel to the base of the toes using a No. 10 scalpel blade and sterile
technique. A small forceps was used to elevate the flexor tendon
from the heel to the toes and to irritate it for 6-8 seconds. The
wound was cleaned and two inverted 6-0 silk sutures were used to
close the incision. Animals were housed individually and
maintained in a 12:12 h light/dark cycle with ad libitum access to
food and water. Separate sets of animals received paw incision
surgery for the ECB tissue concentration studies, the CB1 and CB2
receptor expression and cellular localization studies and the
cannabinoid receptor blockade experiments.
Endocannabinoid Tissue Concentration
Untreated animals received paw incision surgery and were
subjected to deep inhalation of 4% isoflurane in oxygen and
Figure 7. Propentofylline reverses behavioral hypersensitivity
in rats treated with dual CB1/CB2 receptor blockade. 50%
withdrawal thresholds were determined in AM281 + AM630-treated
animals in response to subsequent propentofylline or saline treatment
(indicated by arrows). Animals treated from days 1-9 with mixed CB
antagonists were treated on days 14 and 15 with the glial modulator
propentofylline (50 mgi n1 0ml, i.t., n=7) or saline (10 ml, i.t., n=7).
Behavior was tested before and 3 hours (3h) after injections as shown.
*p,0.05 vs. saline group by two-way ANOVA repeated measures
followed by Bonferroni post tests. BL: Baseline.
doi:10.1371/journal.pone.0010891.g007
AM630-treated rats at postoperative days 9 (A) and 15 (B). Quantification of these markers in laminae I-II is shown in the bottom panel (C). Staining
was quantified as the number of pixels above a set threshold per total pixels in the selected area. Vehicle group: Iba-1-day 9, n=4; Iba-1-day 15, n=8;
GFAP-day 9, n=3; GFAP-day 15, n=8. AM281+AM630 group: Iba-1-day 9, n=4; Iba-1-day 15, n=6; GFAP-day 9, n=3; GFAP-day 15, n=6. *p,0.05 vs.
vehicle group by two-way ANOVA followed by Bonferroni post test.
doi:10.1371/journal.pone.0010891.g006
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(n=6 each). Naı ¨ve animals (n=3) were used as the control group.
The lumbar enlargement of the spinal cord was collected and
dissected with a scalpel to divide the ipsilateral and contralateral
sides (left and right for naı ¨ve animals). The periaqueductal gray
(PAG) was also harvested. Tissues were wrapped in foil and snap
frozen on dry ice and removed to -80 uC until analysis. Frozen
tissues were weighed and homogenized in methanol (1 mL/100
mg of tissue) containing [
2H4]FAEs, [
2H8] 2-AG (Cayman
Chemical, Ann Arbor, MI) and 1-O-Hexadecyl-2-palmitoyl-sn-
glycero-3-phospho-(N-palmitoyl)-ethanolamide (Enzo Life Scienc-
es International, Inc., Plymouth Meeting, PA) as internal
standards. [
2H4]FAEs were synthesized as previously described
[45]. Lipids were extracted with chloroform and water and were
fractionated by open-bed silica gel column chromatography as
previously described [46]. FAEs and 2-AG were quantified as
previously described [47] using an 1100-LC system coupled to a
1946A-MS detector (Agilent Technologies, Inc., Palo Alto, CA)
equipped with an electrospray ionization interface. Quantifications
were conducted using an isotope dilution method, monitoring the
sodium adduct of the molecular ions ([M+Na]
+). We quantified
NAPEs by LC-MS
n using an 1100-LC system (Agilent Technol-
ogies) equipped with an Ion Trap XCT (Agilent Technologies) as
previously described [47]. Tissue-derived NAPEs were identified
by comparison of their LC retention times and MS
n fragmentation
patterns with those of authentic standards, prepared as previously
described [47]. Extracted ion chromatograms were used to
quantify each NAPE precursor ion by monitoring the character-
istic lyso-NAPE product ions in MS
2 using 1-O-Hexadecyl-2-
palmitoyl-sn-glycero-3-phospho-(N-palmitoyl)-ethanolamide (m/z
914.8.676.8) as an internal standard. The following NAPEs were
monitored: 1-stearoyl, 2-arachidonoyl-sn-glycero-3-phosphoetha-
nolamine-N-palmitoyl (m/z 1004.8.718.8), 1-stearoyl, 2-
arachidonoyl-sn-glycero-3-phosphoethanolamine-N-oleoyl (m/z
1030.8.744.6), and 1-stearoyl, 2- docosahexaenoyl-sn-glycero-3-
phosphoethanolamine-N-arachidonoyl (m/z 1076.8.766.8). De-
tection and analysis were controlled by Agilent/Bruker Daltonics
software version 5.2.
Drug Treatment
Animals in the experimental group were treated with intraperito-
neal (i.p.) injections of AM281 (1-(2,4-dichlorophenyl)-5-(4-iodophe-
nyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide; Tocris,
Ellisville, Missouri) and AM630 (6-iodo-2-methyl-1-[2-(4-morpholi-
nyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone; Tocris, Ellis-
ville, Missouri) at a dose of 1 mg.kg
21 each in 500 ml [41,48,49].
AM281 is a diarylpyrazole analog CB1 receptor antagonist/inverse
agonist [50,51]. AM630 is an aminoalkylindole analogue CB2
receptor antagonist/inverse agonist [52,53,54]. Although some
studies indicate that CB1 receptor antagonists may interact with
TRPV1 channels [55] or with the opioid system via prodynorphin
production [49], it is unlikely that our behavioral findings were
Figure 8. Propentofylline reverses over-expression of GFAP and phospho-p38 in rats treated with dual CB1/CB2 receptor blockade.
Representative images show spinal GFAP (A) and phospho-p38 staining (B) in the ipsilateral L5 dorsal horn of animals treated from days 1-9 with
AM281 + AM630 and subsequently treated on days 14 and 15 with the glial modulator propentofylline (PPF, 50 mgi n1 0ml, i.t., n=4) or saline (Sal,
10 ml, i.t., n=3). Staining of GFAP (C) and phospho-p-38 (D) was quantified as the number of pixels above a set threshold per total pixels in the
selected area. Controls (Veh, n=3) were treated with the antagonist vehicle for nine days but did not receive either propentofylline or saline
treatment. *p,0.05 vs. AM281 + AM630/saline group by one-way ANOVA followed by Dunnett’s post test.
doi:10.1371/journal.pone.0010891.g008
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these systems, which do not play a role in paw-incision-induced
hypersensitivity [56,57]. AM281 and AM630 were concomitantly
administered in the morning between 10:00 – 11:00 AM and in the
evening between 4:00 – 5:00 PM on the day of surgery and the
following nine days. A control group was injected with an equivalent
Figure 9. Phospho-p38 is expressed in astrocytes and perivascular microglia. Confocal analysis was used to determine phospho-p38 (P-
p38) cellular localization in the superficial laminae of the ipsilateral L5 dorsal horn in AM281 + AM630-treated rats on day 15 after paw incision.
Representative images are shown. Phospho-p38 appears in green. GFAP (marker for astrocytes), ED2/CD163 (ED2, marker for perivascular microglia),
Iba-1 (marker for microglia) and NeuN (marker for neurons) appear in red. The color of ED2/CD163, Iba-1 and NeuN staining was digitally changed
from green to red, and phospho-p38 from red to green for consistency in presenting the data and in order to allow a better visualization of the co-
localization of these markers. The colors of the GFAP/phospho-p38 co-stain (top panel) were not altered.
doi:10.1371/journal.pone.0010891.g009
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perfused on day 9 did not receive drug or vehicle injections that day.
A subset of animals received i.t. injections of the glial modulator
propentofylline (50 mgi n1 0ml) or saline (10 ml) on days 14 and 15
after surgery.
Behavioral Testing
To test mechanical allodynia, calibrated von Frey filaments
(Stoelting, Wood Dale, IL) were pressed against the plantar aspect
of each hind paw for approximately 6 seconds. The 50%
withdrawal thresholds of each hind paw were determined twice
at 10-15 minute intervals using the up-down statistical method
[58]. The average of these values was used for data analysis. The
untreated animals that provided tissue for the ECB concentration
and CB1 and CB2 receptor expression and cellular localization
studies were tested for baseline values, received paw incision
surgery and were tested before tissue collection on postoperative
days 1, 3, 9 or 15. In both cases, the naı ¨ve animals used for
controls were also tested for baseline behavior but did not receive
paw incision surgery. In the cannabinoid receptor blockade
experiments, animals receiving mixed antagonist or vehicle
treatment (see above) were tested twice before surgery to obtain
a baseline then daily (before the morning injection) over the course
of the 15 days following surgery to monitor the resolution of
hypersensitivity. In a subset of animals, behavior was tested before
antagonist administration and at 30 minutes, 1 hour and 2 hours
after injection; however, since drug administration produced no
acute effects (data not shown), daily behavioral tests for the
majority of animals were only performed once daily (directly
before A.M. drug injections). In the subset of animals that were
additionally injected intrathecally (i.t.) with either propentofylline
(n=7) or saline (n=7) as described above, behavior was tested
before and 3 hours after i.t. injections. During all behavioral
testing, the experimenter was blinded to experimental conditions.
Tissue Preparation for Immunofluorescence and
Immunohistochemistry
In order to examine expression of Iba-1 (a microglial marker),
GFAP (an astrocytic marker), ED2/CD163 (a perivascular cell
marker) and CB1/CB2 receptor and CB1/CB2 receptor co-
localization with other cell markers in response to paw incision,
untreated animals received paw incision surgery and were
perfused as described below on days 1, 3 and 9 after surgery
(n=4 each). Naı ¨ve animals (n=4) were used as the control group.
In separate experiments, animals receiving mixed CB1 and CB2
receptor antagonists (day 9 after surgery, n=4; day 15 after
surgery, n=6) or vehicle (day 9 after surgery, n=4; day 15 after
surgery, n=8) were perfused as described below on days 9 and 15
post-surgery. These animals were used to provide spinal cord
tissue for the analysis of ED2/CD163, Iba-1 and GFAP expression
for the cannabinoid receptor blockade experiments. Another set of
animals received vehicle (n=3), mixed CB1 and CB2 receptor
antagonists followed by propentofylline on days 14 and 15 (n=4)
or mixed CB1 and CB2 receptor antagonists followed by saline
vehicle on days 14 and 15 (n=4). Animals were perfused 3 hours
after propentofylline or saline treatment as described below on day
15 post-surgery. These animals were used to provide spinal cord
tissue for the analysis of GFAP expression and p38 phosphory-
lation.
In all cases, animals were first subjected to deep inhalation of
4% isoflurane in oxygen and perfused transcardially with 0.01 M
phosphate buffered saline (PBS; approximately 150 ml) followed
by 4% formaldehyde (350 ml or until stiff) at room temperature.
After fixation, a laminectomy was performed, the lumbar
enlargement was removed and the L5 segment was separated
and cryoprotected in 30% sucrose for 48–72 h at 4uC. The tissue
was then mounted and frozen in Optimal Cutting Temperature
(O.C.T.) compound (Sakura Finetek, Torrance, CA) at -80uC.
Immunofluorescence was performed on transverse 20 mm sections
of the L5 spinal cord. Sections to be stained for ED2/CD163 were
then post-fixed with 4% formaldehyde for 5 minutes and washed 3
times with 1X PBS wash buffer (.0067 M) for 10 minutes at 4uC
before blocking. This step was omitted for all other stains. All
sections were blocked in 5% Normal Goat Serum (NGS) and
0.01% Triton-X-100 for 1 hour at 4uC. Sections were incubated in
the appropriate primary antibody or antibodies diluted in a buffer
composed of 1% NGS and 1% Triton-X-100 in PBS overnight at
4uC. Microglia were stained with a rabbit polyclonal antibody
directed against Iba-1 (1:1000, Wako Pure Chemical Industries,
Richmond, VA). Astrocytes were stained with a rabbit polyclonal
antibody directed against GFAP (1:10,000, Dako Cytomation,
Glostrup, Denmark) except when co-staining with Iba-1. To avoid
cross-reactivity in this latter case, a mouse polyclonal antibody was
used to stain GFAP (1:400, Sigma, Saint Louis, Missouri).
Perivascular cells were stained with a mouse polyclonal antibody
directed against ED2/CD163 (1:150, Serotec, Raleigh, NC).
Neurons were stained with a mouse polyclonal antibody directed
against Neuronal Nuclei, NeuN (1:10,000, Chemicon, Billerica,
Massachusetts). A rabbit polyclonal antibody was used to label
CB1 receptors (1:200, Cayman, Ann Arbor, MI; except when
using the TSA Signal Amplification Kit, see below). A goat
polyclonal antibody was used to label CB2 receptors (1:150, Santa
Cruz, Santa Cruz, CA). A mouse or rabbit monoclonal antibody
was used to label phospho-p38 (1:100, Cell Signaling, Danvers,
MA). The following day, tissue sections were washed 3 times with
PBS for 10 minutes at 4uC and stained with the appropriate
secondary fluorescent antibody or antibodies diluted 1:250 in a
buffer composed of 1% NGS and 1% Triton-X-100 in PBS for 1
hour at 4uC. For CB2 receptor expression at different time points
following paw incision surgery we used the Vector ELITE ABC
(Vector Labs, Burlingame, CA), avidin-biotin complex technique.
The following secondary antibodies were used as indicated in
Table S2 (Supplemental Material): Alexa-Fluor
TM 488 Goat anti-
Rabbit IgG1 (Molecular Probes, Eugene, Oregon), Alexa-Fluor
TM
488 Goat anti-Mouse IgG1 (Molecular Probes, Eugene, Oregon),
Alexa-Fluor
TM 555 Goat anti-Mouse IgG (Molecular Probes,
Eugene, Oregon) and Alexa-Fluor
TM 555 Donkey anti-Goat IgG
(Molecular Probes, Eugene, Oregon). Alexa-Fluor
TM 488 fluor-
ophore-tagged secondary antibodies emit green wavelengths of
visible light and Alexa-Fluor
TM 555 fluorophore-tagged secondary
antibodies emit red wavelengths of visible light. To avoid cross-
reactivity between the secondary antibodies in the CB2 receptor
co-localization experiments, sections were first incubated in Alexa-
Fluor
TM 555 Donkey anti-Goat IgG (Molecular Probes, Eugene,
Oregon) as described above, washed 2 times in PBS and then
incubated in the appropriate Alexa-Fluor
TM 488 secondary
antibody as described above. This protocol modification prevented
binding of the Alexa-Fluor
TM 555 Donkey anti-Goat IgG to the
goat-derived Alexa-Fluor
TM 488. To avoid cross-reactivity when
co-staining with primary antibodies against Iba-1 and CB1
receptors that are both rabbit-derived, a TSA Signal Amplification
Kit was used following the manufacturer instructions (PerkinElmer
LifeSciences Inc, Boston, MA). On the first day, normal
immunofluorescence protocol was followed except that sections
were incubated only in anti-CB1 receptor antibody at a
concentration of 1:10,000. On the second day sections were
washed 2 times for 5 minutes in PBS then incubated in a
biotinylated Goat a Rabbit secondary antibody for 1 hour at 4uC.
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HRP (1:100) for 1 hour at 4uC, washed again and incubated in the
TSA fluorophore (1:250) for 10 minutes at 4uC. Sections were then
washed again and incubated overnight in the Iba-1 primary
antibody (1:1000). The next day sections were subjected to normal
day 2 immunofluorescence protocol to visualize Iba-1 (described
above). One control was included with only the anti-CB1 receptor
primary antibody (1:10,000) and the Alexa 555 Goat a Rabbit
secondary antibody to control for any cross-reactivity that might
cause CB1 receptor staining to appear in red. A second control
included only the anti-CB1 receptor primary antibody and the
TSA kit in order to visualize the staining achieved in the absence
of the co-stain. Finally, a third control included the TSA kit, Iba-1
primary and the Alexa 555 Goat a Rabbit secondary antibody but
excluded the anti-CB1 receptor primary antibody. This third
control provided visualization of the non-specific background
staining produced by the kit alone. All controls confirmed the
specificity of the complete co-stain.
In all cases, tissue sections were washed again as before,
mounted on glass slides, dehydrated, treated with Vectashield
(Vector Labs, Burlingame, CA) and sealed with a coverslip and
nail polish. The specificity of each antibody was tested by omitting
the primary antibody on 1-3 additional sections.
Imaging and Image Analysis
The induction of glial reactivity has been described as an
increase in the number (proliferation and/or migration) and
complexity of these populations (rounded cell bodies and thicker
processes), resulting in an increase in the expression of glial
markers. However, the role of common glial markers in
determining glial phenotype is not well understood. In order to
better assess the induction of inflammatory activity in CNS cell
populations, we also studied the expression of the pro-inflamma-
tory mitogen activated protein kinase (MAPK) p38 in its active
form (phosphorylated) in glial and neuronal cells. In order to
quantify these markers, stained sections were examined with an
Olympus fluorescence microscope, and images were captured with
a Q-Fire cooled camera (Olympus, Melville, NY). In the
superficial laminae (I-II) and deep laminae (III-V) of the L5 dorsal
horn, the intensity of CB1 receptor, CB2 receptor, Iba-1, GFAP
and phospho-p38 staining was quantified as the number of pixels
per area above a preset intensity threshold using SigmaScan Pro 5
(SPSS, Chicago, IL) as previously described [3,17]. For each area,
the number of high-intensity pixels was normalized to the total
pixels selected in that area. For each animal, 4 sections were
analyzed, and an average of these values was used for statistical
analysis. To ensure the consistency of staining technique between
groups, immunofluorescent/immunohistochemical staining and
image capture were both performed simultaneously on all tissue
samples that were directly compared and subjected to statistical
tests. Due to the relatively small volume of ED2/CD163 positive
cells, this marker was quantified by counting positively stained cells
on an Olympus fluorescence microscope.
Statistical Analysis
For behavioral data and comparison against base line or day 1
after surgery, one-way ANOVA repeated measures was conduct-
ed and followed by Dunnett’s or Bonferroni multiple comparison
post test (only when p,0.05 was found). Two-way ANOVA
repeated measures was used for comparisons between groups at
every time point for behavioral data, and followed by Bonferroni
post tests when p,0.05 was found. To compare relative CB1
receptor, CB2 receptor and ED2/CD163 staining and tissue
concentrations of ECBs, their precursors and other non-
cannabinoid ethanolamides over time, one-way ANOVA fol-
lowed by Dunnett’s multiple comparison post test, when p,0.05
was found, was performed. Two-way ANOVA plus Bonferroni
post tests when p,0.05 was used for comparisons between groups
for Iba-1 or GFAP expression. All data are presented as the mean
6 SEM. In all cases a p,0.05 was considered significant.
GraphPad Prism 5 software was used to perform all statistical
analyses.
Supporting Information
Figure S1 Spinal OEA and PEA concentrations do not change
after paw incision. Concentrations of OEA and PEA were
measured in naı ¨ve rats (N, n=3) and ipsilateral and contralateral
to paw incision in rats at days 1 (D1), 3 (D3), 9 (D9) and 15 (D15)
after surgery (n=6 for each group). OEA: N-oleoylethanolamine,
PEA: palmitoylethanolamide. No significant difference was found
between groups using one-way ANOVA (p.0.05).
Found at: doi:10.1371/journal.pone.0010891.s001 (4.47 MB TIF)
Figure S2 PEA levels in the PAG are reduced after paw incision.
PAG concentrations of OEA, PEA, AEA and 2-AG were
measured in naı ¨ve rats (N, n=3) and at days 1 (D1), 3 (D3), 9
(D9) and 15 (D15) after surgery in rats receiving paw incision
(n=6 for each group). *p,0.05 vs. naive group by one-way
ANOVA followed by Dunnett’s post test. 2-AG: 2-Arachidonoyl-
glycerol, AEA: Anandamide, OEA: N-oleoylethanolamine, PEA:
palmitoylethanolamide.
Found at: doi:10.1371/journal.pone.0010891.s002 (3.59 MB TIF)
Figure S3 CB1 receptor expression is reduced on days 1 and 9
after paw incision. Representative images (A) show CB1 receptor
staining in the L5 dorsal horn of naı ¨ve rats (N, n=3) and
ipsilateral to paw incision in rats at days 1 (D1, n=3), 3 (D3, n=3)
and 9 (D9, n=4) after surgery. The middle panel (B) shows detail
of the superficial laminae (I-II) of the dorsal horn of these spinal
cord sections. Staining was quantified (C) as the number of pixels
above a set threshold per total pixels in the selected area. *p,0.05
vs. naive by one-way ANOVA followed by Dunnett’s post test.
Found at: doi:10.1371/journal.pone.0010891.s003 (2.66 MB TIF)
Figure S4 CB2 receptor expression is increased on day 1
following paw incision. Representative images (A) show CB2
receptor staining in the L5 dorsal horn of naı ¨ve rats (N, n=3) and
ipsilateral to paw incision in rats at days 1 (D1, n=3), 3 (D3, n=3)
and 9 (D9, n=4) after surgery. The middle panel (B) shows detail
of the superficial laminae (I-II) of the dorsal horn of these spinal
cord sections. Staining was quantified (C) as the number of pixels
above a set threshold per total pixels in the selected area. These
representative images have been digitally transformed to black and
white color. *p,0.05 vs. naive group by one-way ANOVA
followed by Dunnett’s post test.
Found at: doi:10.1371/journal.pone.0010891.s004 (2.86 MB TIF)
Table S1 Tissue Concentrations of Fatty Acid Ethanolamide
Precursors. Levels of N-acylphosphatidylethanolamine species
precursors in the spinal cord and perieaqueductal grey (PAG) of
naı ¨ve rats and of rats at days 1, 3, 9 and 15 after paw incision
surgery. No significant differences were found between groups for
any of these compounds using one-way ANOVA (p.0.05). I:
ipsilateral to paw incision, C: contralateral to paw incision, NAPE:
N-arachidonoylphosphatidylethanolamine, NPPE: N-palmitoyl-
phosphatidylethanolamine, NOPE: N-oleoylphosphatidylethano-
lamine. Data presented as mean (s.e.m.).
Found at: doi:10.1371/journal.pone.0010891.s005 (0.07 MB
DOC)
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istry and immunofluorescence experiments. CB1: Cannabinoid
Type 1, CB2: Cannabinoid Type 2, ED2: Perivascular cell marker,
GFAP: Glial Fibrillary Acidic Protein, Iba-1: Ionized Calcium-
Binding Adapter Molecule 1, NeuN: Neuronal Nuclei.
Found at: doi:10.1371/journal.pone.0010891.s006 (0.09 MB
DOC)
Video S1 Low levels of CB1 receptor are expressed in spinal
astrocytes. Analysis of Z-stacked confocal images was used to
confirm CB1 receptor colocalization with GFAP-positive astro-
cytes in the superficial laminae of the L5 dorsal horn of naı ¨ve rats.
CB1 receptor staining appears in red. GFAP (marker for
astrocytes) appears in grey. In these images, GFAP staining
originally appeared in green. The the color of GFAP staining was
digitally changed to grey in order to allow better visualization of
occasional staining of CB1 receptors on GFAP-positive cells.
Found at: doi:10.1371/journal.pone.0010891.s007 (7.08 MB AVI)
Video S2 Low levels of CB1 receptor are expressed in spinal
astrocytes at day 9 after paw incision. Analysis of Z-stacked
confocal images was used to confirm CB1 receptor colocalization
with GFAP-positive astrocytes in the superficial laminae of the L5
dorsal horn at day 9 after paw incision surgery. CB1 receptor
staining appears in red. GFAP (marker for astrocytes) appears in
grey. In these images, GFAP staining originally appeared in green.
The color of GFAP staining was digitally changed to grey in order
to allow better visualization of occasional staining of CB1 receptors
on GFAP-positive cells.
Found at: doi:10.1371/journal.pone.0010891.s008 (7.08 MB AVI)
Video S3 Low levels of CB2 receptor are expressed in neuronal
somata. Analysis of Z-stacked confocal images was used to confirm
CB2 receptor colocalization with NeuN-positive neuronal somata
in the superficial laminae of the L5 dorsal horn at day 3 after paw
incision surgery. CB2 receptor staining appears in red. NeuN
(neuronal marker) appears in green.
Found at: doi:10.1371/journal.pone.0010891.s009 (11.80 MB
AVI)
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